1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Real-time Estimate Cboe BZX  -  05/23 02:29:38 pm EDT
137.94 USD   +1.24%
02:07pWhat's next for COVID-19 vaccines for youngest US children
AQ
11:48aPfizer says 3 COVID shots protect children under 5
AQ
10:26aPfizer says 3 shots of COVID-19 vaccine for children under 5 about 80% effective
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EMA Says Spikevax Product Information To Be Updated To Include Paraesthesia As Rare Side Effect

01/20/2022 | 06:49am EDT

Jan 20 (Reuters) - European Medicines Agency:

* EMA: ASSESSMENT OF WHETHER VACCINATION CAN CAUSE CAPILLARY LEAK SYNDROME (IS ONGOING FOR PFIZER AND MODERNA COVID-19 VACCINES

* EMA SAYS FOR SPIKEVAX, PRODUCT INFORMATION WILL BE UPDATED TO INCLUDE PARAESTHESIA (UNUSUAL FEELING IN THE SKIN) AS A RARE SIDE EFFECT

* EMA: IN JANUARY 2022, PRAC CONCLUDED THAT TRANSVERSE MYELITIS SHOULD BE ADDED TO THE PRODUCT INFORMATION AS A SIDE EFFECT OF ASTRAZENECA VACCINE Further company coverage:


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.71% 10568 Delayed Quote.20.93%
MODERNA, INC. 1.28% 138.02 Delayed Quote.-46.35%
PFIZER, INC. 1.24% 53.14 Delayed Quote.-11.14%
All news about MODERNA, INC.
02:07pWhat's next for COVID-19 vaccines for youngest US children
AQ
11:48aPfizer says 3 COVID shots protect children under 5
AQ
10:26aPfizer says 3 shots of COVID-19 vaccine for children under 5 about 80% effective
AQ
08:39aWhat you need to know about the coronavirus right now
RE
07:19aINSIDER SELL : Moderna
MT
05/19EU health regulator backs using AstraZeneca COVID shot as booster
RE
05/18Moderna Seeks Swissmedic Nod For COVID-19 Shot In Children Aged Six Months To Five year..
MT
05/18As COVID cases rise, U.S. health officials mull widening additional booster eligibility
RE
05/18Moderna, International AIDS Vaccine Initiative to Start Volunteer Screening for Phase 1..
MT
05/18Piper Sandler Adjusts Moderna's Price Target to $214 From $348, Reiterates Overweight R..
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 069 M - -
Net income 2022 11 501 M - -
Net cash 2022 18 081 M - -
P/E ratio 2022 5,01x
Yield 2022 -
Capitalization 54 195 M 54 195 M -
EV / Sales 2022 1,64x
EV / Sales 2023 3,33x
Nbr of Employees 2 700
Free-Float 90,6%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 136,25 $
Average target price 212,69 $
Spread / Average Target 56,1%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567
ALNYLAM PHARMACEUTICALS, INC.-22.00%15 980